Journal article
Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
Abstract
BackgroundOptimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving.MethodsPatients receiving BMA for bone metastases from breast or CRPC were surveyed. Information was collected on patient and disease characteristics, BMA treatments and perceptions regarding BMA benefits and side effects. Interest in participation in trials of de-escalated BMA …
Authors
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C
Journal
Supportive Care in Cancer, Vol. 29, No. 11, pp. 6903–6912
Publisher
Springer Nature
Publication Date
November 2021
DOI
10.1007/s00520-021-06238-1
ISSN
0941-4355